Contents hide 1 Melanoma 1.1 BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma 1.2 Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma 2 Non-Small Cell Lung Cancer 3 Thyroid Cancer 4 BRAF V600E Mutation-Positive Solid Tumors Trametinib is a kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer. Melanoma Also see Administration Mutations must be detected by an FDA-approved test BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma Indicated, as a single agent or in combination with dabrafenib 2 mg PO … Continue reading Generic (Trametinib) TRAMEDX